Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
Saif
Muhammad Wasif
MW
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D021441:Carcinoma, Pancreatic Ductal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D047495:PPAR gamma / Q000037:antagonists & inhibitors / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D010195:Pancreatitis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors / Q000378:metabolism
D000970:Antineoplastic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016328:NF-kappa B; D047495:PPAR gamma; D017382:Reactive Oxygen Species